In the context of oncology, notable HER2 overexpression has been documented in cases of breast, gastric and ovarian cancers, indicating its relevance in the pathophysiology and its potential value as a therapeutic target of these cancers (Hofheinz et al., 2023; Kim et al., 2024). Here, ERBB2 is linked to cancer.